Bayer: Science For A Better Life - research

Innovative thrombosis prevention

Combating dangerous blood clots

Successful against thrombosis: The photomontage shows thrombosis researcher Dr. Elisabeth Perzborn and the platelets that are partly responsible for vascular occlusion (purple).

Pulmonary embolism causes death more frequently than most people think. What's more, it usually appears harmless at first: the sufferer's calf aches, just like it would after unaccustomed exercise. If a blood clot has already formed, however, the condition can quickly become critical. A preventive substance developed by Bayer HealthCare could help to considerably reduce the risk.

More safety in thrombosis prevention

At present, conventional thrombosis prevention primarily involves low-molecular-weight heparin or coumarin derivatives, both of which have their drawbacks: heparins are only effective when injected subcutaneously, while accurately gauging the correct dosage of coumarin derivatives requires a lot of careful attention from the attending physician. One ray of hope may be concealed behind the sober designation BAY 59-7939. This substance, a novel Factor Xa inhibitor, promises to have a number of advantages over conventional treatments. Find out more about the current state of development of this new substance in the following article (PDF file).